Calendar Modus Therapeutics Holding AB

Equities

MODTX

SE0015987904

Market Closed - Nasdaq Stockholm 11:08:54 2024-05-31 am EDT 5-day change 1st Jan Change
1.075 SEK -2.71% Intraday chart for Modus Therapeutics Holding AB +3.86% -38.04%

Chart calendar Modus Therapeutics Holding AB

af4942da9d13.61yCinftCHGftBu1APhm2S9jXKNqUMI7_45GJAqtV-M.nDmxzjuobxjvjGzeWrpTr2YnOM1SA6pzvt5rZUHoHKCYM8i_EoFdJcvBWg~23c4e1c1302e8c8688bcbba8ff448e16

Upcoming events on Modus Therapeutics Holding AB

2024-08-22 Q2 2024 Earnings Release
2024-11-19 Q3 2024 Earnings Release
2025-02-19 Q4 2024 Earnings Release
2025-05-19 Q1 2025 Earnings Release (Projected)
2025-08-20 Q2 2025 Earnings Release (Projected)
2025-11-18 Q3 2025 Earnings Release (Projected)
2026-02-24 Q4 2025 Earnings Release (Projected)

Past events on Modus Therapeutics Holding AB

2024-05-16 Annual General Meeting
2024-05-13 Q1 2024 Earnings Release
2024-02-20 Q4 2023 Earnings Release
2023-11-21 Q3 2023 Earnings Release
2023-08-24 Q2 2023 Earnings Release
2023-05-08 Q1 2023 Earnings Release
2023-02-21 FY 2022 Earnings Release
2022-11-21 Q3 2022 Earnings Release
2022-08-22 Interim 2022 Earnings Release
2022-05-15 Q1 2022 Earnings Release
2022-05-10 Annual General Meeting
2022-02-21 FY 2021 Earnings Release
2021-11-18 09:00 am Q3 2021 Earnings Release

Annual results

Fiscal PeriodDecember 2020 2021 2023 2024
Net sales
Million SEK
Released
Forecast
Spread
0,00


0,00
0,00
-
0,00



0,00

EBITDA
Million SEK
Released
Forecast
Spread
0,00


-20,7
-16,3
-26.93%
0,00



-18,0

EBIT
Million SEK
Released
Forecast
Spread
0,00


-20,7
-16,3
-26.93%
0,00



-18,0

Earnings before Tax (EBT)
Million SEK
Released
Forecast
Spread
0,00


0,00
0,00
-
0,00



-18,0

Net income
Million SEK
Released
Forecast
Spread
-6,02


0,00
0,00
-
-17,9



-18,0

EPS
SEK
Released
Forecast
Spread
0,00


0,00
0,00
-
-1,01



-0,50

Announcement Date14/04/2122/02/2221/02/24-

Net sales - Annual - Rate of surprise

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. MODTX Stock
  4. Calendar Modus Therapeutics Holding AB